Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Boehringer Ingelheim
Eli Lilly and Company
Washington University School of Medicine
OHSU Knight Cancer Institute
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC